Biotech Values

[poorgradstudent]

GLPG / ABBV:

I thought the data especially for ACR-70 were particularly strong.

I think overall the efficacy data were strong. The 100 or 200 mg total dose seems to be the way to go, and efficacy across those doses doesn't look too different to me. The numbers bounce around a bit, which suggests they're at the top of the efficacy range. For example, ACR70 has 100 mg > 200 mg if once a day but 200 mg > 100 mg if through twice a day dosing. No big deal, and it suggests they zoned in on a good dose range.

Will be interesting to see what ABBV does. They still need to run phase 3 trials for filgotinib, so perhaps ABBV may consider the opportunity-cost of how quickly they can get their internal candidate into phase 3 versus filgotinib? Might be expensive to lug 2 overlapping candidates through phase 3 trials in RA.